Their observations demonstrated that a combination treatment using HDAC inhibitors and PPARγ agonists inhibits invasion of prostate cancer cells in vivo, through upregulation of E-cadherin expression [98]. This evidence concerns the gene HDAC9 and prostate carcinoma.